Researchers assessed balugrastim’s efficacy, safety, and tolerability in 4 different clinical trials and found it to be a suitable alternative to pegfilgrastim in regard to reducing the mean duration of severe neutropenia.
Balugrastim, a new long-lasting recombinant granulocyte colony-stimulating factor, is an alternative to pegfilgrastim in regard to reducing the mean duration of severe neutropenia. Researchers assessed balugrastim’s efficacy, safety, and tolerability in 4 different clinical trials involving breast cancer patients treated with doxorubicin and doxetaxel, and published their findings in Therapeutics and Clinical Risk Management.
Neutropenia and febrile neutropenia are 2 frequent complications of chemotherapy treatment and recombinant granulocyte colony-stimulating factors are used to preserve absolute neutrophils count throughout the duration of chemotherapy treatment.
Thus far there has been limited literature available on balugrastim. The researchers assessed the available studies and found that balugrastim did not cause any severe adverse events or compromise quality of life. The administration of balugrastim was found to be extremely safe, and it had a slight advantage over pegfilgrastim in shortening the mean time to absolute neutrophils count recovery.
However, since all the studies analyzed were performed in homogenous populations of breast cancer patients treated with docetaxel and doxorubicin, the authors recommend additional research involving different tumor types and chemotherapy combinations, as well as long-term studies to adequately evaluate the safety of balugrastim.
Downward Morbidity, Mortality Trends Discovered Among Patients With Ovarian Cancer, Liver Metastases
April 24th 2024This study indicates a declining trend in morbidity and mortality rates among patients with ovarian cancer and liver metastases, highlighting the efficacy of surgery and chemotherapy in improving survival outcomes.
Read More
Oncology Onward: A Conversation With Penn Medicine's Dr Justin Bekelman
December 19th 2023Justin Bekelman, MD, director of the Penn Center for Cancer Care Innovation, sat with our hosts Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, for our final episode of 2023 to discuss the importance of collaboration between academic medicine and community oncology and testing innovative cancer care delivery in these settings.
Listen